首页 > 最新文献

Annals of thoracic surgery short reports最新文献

英文 中文
Multiple Lung Resections for Metastases from Pheochromocytoma to Reduce Catecholamine Production 对嗜铬细胞瘤转移灶进行多次肺部切除,以减少儿茶酚胺的分泌
Pub Date : 2024-09-01 DOI: 10.1016/j.atssr.2024.01.010

A pheochromocytoma is a malignant tumor with metastatic potential. Moreover, the cardiovascular effects of abnormal amounts of catecholamines resulting from pheochromocytoma impact prognosis. Resection of the primary tumor is useful for reducing catecholamine production; however, the significance of resection of metastases remains unclear. Herein, we report a case in which multiple lung resections for metastases from pheochromocytoma were performed 5 years after primary tumor resection. Complete resection of 6 pulmonary lesions was achieved, maintaining reduced catecholamine levels and blood pressure without any sign of recurrence for a year.

嗜铬细胞瘤是一种具有转移潜力的恶性肿瘤。此外,嗜铬细胞瘤产生的异常儿茶酚胺会对心血管产生影响,从而影响预后。切除原发肿瘤有助于减少儿茶酚胺的产生,但切除转移瘤的意义尚不明确。在此,我们报告了一例在原发肿瘤切除 5 年后因嗜铬细胞瘤转移而进行多次肺部切除的病例。该病例完全切除了 6 个肺部病灶,儿茶酚胺水平和血压维持在较低水平,一年来未出现任何复发迹象。
{"title":"Multiple Lung Resections for Metastases from Pheochromocytoma to Reduce Catecholamine Production","authors":"","doi":"10.1016/j.atssr.2024.01.010","DOIUrl":"10.1016/j.atssr.2024.01.010","url":null,"abstract":"<div><p>A pheochromocytoma is a malignant tumor with metastatic potential. Moreover, the cardiovascular effects of abnormal amounts of catecholamines resulting from pheochromocytoma impact prognosis. Resection of the primary tumor is useful for reducing catecholamine production; however, the significance of resection of metastases remains unclear. Herein, we report a case in which multiple lung resections for metastases from pheochromocytoma were performed 5 years after primary tumor resection. Complete resection of 6 pulmonary lesions was achieved, maintaining reduced catecholamine levels and blood pressure without any sign of recurrence for a year.</p></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772993124000949/pdfft?md5=02bde42928c96070316ecab2f7b15401&pid=1-s2.0-S2772993124000949-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139966331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Double Transposition and Physician-Modified Endografting for Complex Arch Aneurysm 治疗复杂弓状动脉瘤的双层移位术和医生改良内膜移植术
Pub Date : 2024-09-01 DOI: 10.1016/j.atssr.2024.05.020

Hybrid repair of complex aortic arch disease typically requires aortic debranching to create a proximal landing zone for completion arch endografting. Despite advances in endograft technology, physician-modified endografting may be required to customize a prosthesis for challenging anatomy. We present a case of a complex distal arch aneurysm after a prior coarctation repair with a pediatric interposition graft several decades earlier, treated with hybrid repair by double transposition for arch debranching and physician-modified arch endografting for complete aneurysm exclusion.

复杂主动脉弓疾病的混合修复通常需要主动脉去瓣,为完成主动脉弓内膜移植创造近端着床区。尽管内膜移植技术在不断进步,但仍可能需要医生修改内膜移植,以便针对具有挑战性的解剖结构定制假体。我们介绍了一例复杂的远端弓状动脉瘤病例,患者曾在几十年前使用儿科间位移植进行过动脉瘤修补术,当时采用了双转位混合修补术进行弓状支路剥离,并使用医生改良的弓状内膜移植术完全排除动脉瘤。
{"title":"Double Transposition and Physician-Modified Endografting for Complex Arch Aneurysm","authors":"","doi":"10.1016/j.atssr.2024.05.020","DOIUrl":"10.1016/j.atssr.2024.05.020","url":null,"abstract":"<div><p>Hybrid repair of complex aortic arch disease typically requires aortic debranching to create a proximal landing zone for completion arch endografting. Despite advances in endograft technology, physician-modified endografting may be required to customize a prosthesis for challenging anatomy. We present a case of a complex distal arch aneurysm after a prior coarctation repair with a pediatric interposition graft several decades earlier, treated with hybrid repair by double transposition for arch debranching and physician-modified arch endografting for complete aneurysm exclusion.</p></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772993124002389/pdfft?md5=8061093a47c4ac4923783784c5f34eaa&pid=1-s2.0-S2772993124002389-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141416402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Surgical Treatment for Thymoma-Related Stiff Person Syndrome 手术治疗胸腺瘤相关僵人综合征的疗效
Pub Date : 2024-09-01 DOI: 10.1016/j.atssr.2024.01.004

Stiff person syndrome (SPS) is a neurologic disorder, some cases of which are associated with malignant disease. Here, we report a case of thymoma-associated SPS that was successfully treated with surgical resection. A 57-year-old man with progressive muscle stiffness and weakness was diagnosed with thymoma-related SPS. After administration of medication and intravenous immunoglobulin, the patient underwent extended thymectomy, partial pericardial resection, and pericardial reconstruction. After tumor resection, the symptoms gradually diminished, and performance status and respiratory function improved significantly. This report indicates that tumor resection may improve respiratory function, eliminate dyspnea, and improve performance status in tumor-related SPS.

僵人综合征(SPS)是一种神经系统疾病,其中一些病例与恶性疾病有关。在此,我们报告了一例胸腺瘤相关 SPS 病例,该病例通过手术切除获得了成功治疗。一名 57 岁的男性被诊断为胸腺瘤相关性 SPS,并伴有进行性肌肉僵硬和无力。在服用药物和静脉注射免疫球蛋白后,患者接受了扩大胸腺切除术、心包部分切除术和心包重建术。肿瘤切除后,患者症状逐渐减轻,表现状态和呼吸功能明显改善。本报告表明,肿瘤切除术可改善肿瘤相关性 SPS 患者的呼吸功能,消除呼吸困难,改善患者的表现状态。
{"title":"Efficacy of Surgical Treatment for Thymoma-Related Stiff Person Syndrome","authors":"","doi":"10.1016/j.atssr.2024.01.004","DOIUrl":"10.1016/j.atssr.2024.01.004","url":null,"abstract":"<div><p>Stiff person syndrome (SPS) is a neurologic disorder, some cases of which are associated with malignant disease. Here, we report a case of thymoma-associated SPS that was successfully treated with surgical resection. A 57-year-old man with progressive muscle stiffness and weakness was diagnosed with thymoma-related SPS. After administration of medication and intravenous immunoglobulin, the patient underwent extended thymectomy, partial pericardial resection, and pericardial reconstruction. After tumor resection, the symptoms gradually diminished, and performance status and respiratory function improved significantly. This report indicates that tumor resection may improve respiratory function, eliminate dyspnea, and improve performance status in tumor-related SPS.</p></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772993124000858/pdfft?md5=8186cd39047aedc39f899f4c1df011f6&pid=1-s2.0-S2772993124000858-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142129504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impella 5.5 Use in the Setting of Severe Aortic Insufficiency: A Relative Contraindication 在严重主动脉瓣关闭不全的情况下使用 Impella 5.5:相对禁忌症
Pub Date : 2024-09-01 DOI: 10.1016/j.atssr.2024.04.012

Moderate or severe aortic insufficiency is a contraindication to transvalvular Impella left ventricular assist device (Abiomed) use out of concern for worsening valvular insufficiency and recirculation. This report describes the case of a 75-year-old man with severe eccentric aortic insufficiency and systemic hypoperfusion who was supported with a transvalvular Impella 5.5 device for 6 days as preoperative rehabilitation before aortic valve replacement. The Impella device provided adequate systemic tissue perfusion, and left ventricular function remained without signs of volume overload and recirculation. Moderate or severe aortic insufficiency may not be an absolute contraindication to transvalvular Impella use, although this is case dependent.

出于对瓣膜功能不全恶化和再循环的担忧,中度或重度主动脉瓣关闭不全是经瓣 Impella 左心室辅助装置(Abiomed)的禁忌症。本报告描述了一名 75 岁男性患者的病例,他患有严重的偏心性主动脉瓣关闭不全和全身灌注不足,在主动脉瓣置换术前,他使用经瓣 Impella 5.5 装置支持了 6 天,作为术前康复治疗。Impella 装置提供了充足的全身组织灌注,左心室功能保持良好,没有出现容量超负荷和再循环的迹象。中度或重度主动脉瓣关闭不全可能不是经瓣 Impella 装置的绝对禁忌症,但这取决于具体情况。
{"title":"Impella 5.5 Use in the Setting of Severe Aortic Insufficiency: A Relative Contraindication","authors":"","doi":"10.1016/j.atssr.2024.04.012","DOIUrl":"10.1016/j.atssr.2024.04.012","url":null,"abstract":"<div><p>Moderate or severe aortic insufficiency is a contraindication to transvalvular Impella left ventricular assist device (Abiomed) use out of concern for worsening valvular insufficiency and recirculation. This report describes the case of a 75-year-old man with severe eccentric aortic insufficiency and systemic hypoperfusion who was supported with a transvalvular Impella 5.5 device for 6 days as preoperative rehabilitation before aortic valve replacement. The Impella device provided adequate systemic tissue perfusion, and left ventricular function remained without signs of volume overload and recirculation. Moderate or severe aortic insufficiency may not be an absolute contraindication to transvalvular Impella use, although this is case dependent.</p></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772993124001931/pdfft?md5=9e292501f338692b7c2e562015e9999a&pid=1-s2.0-S2772993124001931-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142129468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cavoatrial Bypass for Cardiac Complications From Rosai-Dorfman Disease 治疗罗赛-多夫曼病心脏并发症的腔心房旁路术
Pub Date : 2024-09-01 DOI: 10.1016/j.atssr.2024.03.003

Rosai-Dorfman disease (RDD) is a nonmalignant disease of histiocyte proliferation. RDD usually presents with painless cervical lymphadenopathy, although extranodal involvement can occur. Cardiac involvement was reported in <0.1% of cases. We present a case of cardiac RDD with obstruction at the inferior vena cava-right atrial junction.

罗赛-多夫曼病(RDD)是一种组织细胞增生的非恶性疾病。RDD 通常表现为无痛性颈淋巴结病,但也可发生结节外受累。据报道,0.1%的病例累及心脏。我们介绍了一例下腔静脉-右心房交界处阻塞的心脏RDD病例。
{"title":"Cavoatrial Bypass for Cardiac Complications From Rosai-Dorfman Disease","authors":"","doi":"10.1016/j.atssr.2024.03.003","DOIUrl":"10.1016/j.atssr.2024.03.003","url":null,"abstract":"<div><p>Rosai-Dorfman disease (RDD) is a nonmalignant disease of histiocyte proliferation. RDD usually presents with painless cervical lymphadenopathy, although extranodal involvement can occur. Cardiac involvement was reported in &lt;0.1% of cases. We present a case of cardiac RDD with obstruction at the inferior vena cava-right atrial junction.</p></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772993124001268/pdfft?md5=9f94d604070961009cd2b195c7025590&pid=1-s2.0-S2772993124001268-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140403466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Segmentectomy vs Lobectomy for Non-Small Cell Lung Cancer: The Impact of Tumor Location 非小细胞肺癌的分段切除术与肺叶切除术:肿瘤位置的影响
Pub Date : 2024-09-01 DOI: 10.1016/j.atssr.2024.01.014

Background

The technical complexity of segmentectomy and preservation of lung parenchyma compared with lobectomy vary by lobe. This study evaluated the impact of non-small cell lung cancer tumor location on segmentectomy use and outcomes.

Methods

Outcomes after lobectomy or segmentectomy for cT1N0M0 (≤2 cm) non-small cell lung cancer patients stratified by tumor location in smaller (right upper/middle) vs larger (bilateral lower/left upper) lobes were evaluated with logistic regression, Kaplan-Meier curves, and Cox proportional hazards methods.

Results

A minority of patients in the cohort (N = 31,243) underwent segmentectomy (n = 2783, 9%). Segmentectomy was more common for tumors in larger compared with smaller lobes (11.8% vs 5.1%, P < .001). Major morbidity after segmentectomy was significantly lower than lobectomy for both smaller (2.6% vs 5.7%, odds ratio, 0.41, P < .001) and larger (2.5% vs 5.2%, odds ratio, 0.46, P < .001) lobes. Segmentectomy was associated with smaller lymph node harvest for both types of lobes (small lobes 7.0 vs 10.5, P < .001; large lobes 7.5 vs 10.4, P < .001) but did not compromise survival in multivariate analysis for both small (hazard ratio, 0.99, P = .9) and large (hazard ratio, 1.05, P = .34) lobes.

Conclusions

Segmentectomy that does not compromise oncologic principles should be considered if complete resection is feasible regardless of tumor location.

背景与肺叶切除术相比,肺段切除术的技术复杂性和保留肺实质的程度因肺叶而异。本研究评估了非小细胞肺癌肿瘤位置对分段切除术的使用和结果的影响。方法采用逻辑回归、Kaplan-Meier曲线和Cox比例危险度法评估了cT1N0M0(≤2厘米)非小细胞肺癌患者肺叶切除术或肺段切除术后的疗效,并按肿瘤位置分层,小叶(右上/中叶)与大叶(双侧下/左上叶)。大叶肿瘤的分段切除术比小叶肿瘤的分段切除术更常见(11.8% vs 5.1%,P < .001)。对于较小的肺叶(2.6% vs 5.7%,几率比 0.41,P < .001)和较大的肺叶(2.5% vs 5.2%,几率比 0.46,P < .001),分段切除术后的主要发病率明显低于肺叶切除术。分段切除术与两类肺叶较小的淋巴结摘除有关(小肺叶 7.0 vs 10.5,P < .001;大肺叶 7.5 vs 10.4,P < .001),但在多变量分析中,小肺叶(危险比为 0.99,P = .9)和大肺叶(危险比,1.05,P = .34)。结论无论肿瘤位置如何,如果可行完全切除术,则应考虑不损害肿瘤学原则的分段切除术。
{"title":"Segmentectomy vs Lobectomy for Non-Small Cell Lung Cancer: The Impact of Tumor Location","authors":"","doi":"10.1016/j.atssr.2024.01.014","DOIUrl":"10.1016/j.atssr.2024.01.014","url":null,"abstract":"<div><h3>Background</h3><p>The technical complexity of segmentectomy and preservation of lung parenchyma compared with lobectomy vary by lobe. This study evaluated the impact of non-small cell lung cancer tumor location on segmentectomy use and outcomes.</p></div><div><h3>Methods</h3><p>Outcomes after lobectomy or segmentectomy for cT1N0M0 (≤2 cm) non-small cell lung cancer patients stratified by tumor location in smaller (right upper/middle) vs larger (bilateral lower/left upper) lobes were evaluated with logistic regression, Kaplan-Meier curves, and Cox proportional hazards methods.</p></div><div><h3>Results</h3><p>A minority of patients in the cohort (N = 31,243) underwent segmentectomy (n = 2783, 9%). Segmentectomy was more common for tumors in larger compared with smaller lobes (11.8% vs 5.1%, <em>P</em> &lt; .001). Major morbidity after segmentectomy was significantly lower than lobectomy for both smaller (2.6% vs 5.7%, odds ratio, 0.41, <em>P</em> &lt; .001) and larger (2.5% vs 5.2%, odds ratio, 0.46, <em>P</em> &lt; .001) lobes. Segmentectomy was associated with smaller lymph node harvest for both types of lobes (small lobes 7.0 vs 10.5, <em>P</em> &lt; .001; large lobes 7.5 vs 10.4, <em>P</em> &lt; .001) but did not compromise survival in multivariate analysis for both small (hazard ratio, 0.99, <em>P</em> = .9) and large (hazard ratio, 1.05, <em>P</em> = .34) lobes.</p></div><div><h3>Conclusions</h3><p>Segmentectomy that does not compromise oncologic principles should be considered if complete resection is feasible regardless of tumor location.</p></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772993124000986/pdfft?md5=5a0ce8faec1c8a039bd43ad3b7d4b138&pid=1-s2.0-S2772993124000986-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140464750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Scenic Route: Lingular Metastasectomy Through the Right Chest 风景之路穿透右胸的舌状转移切除术
Pub Date : 2024-09-01 DOI: 10.1016/j.atssr.2024.03.010

Metastasectomy for isolated pulmonary metastasis can improve disease-free and overall-survival in well-selected patients. When feasible, a minimally invasive wedge resection is the preferred approach. However, a hostile ipsilateral chest can hinder surgical resection. In this report, we describe the resection of an isolated metastasis in the lingula through the right chest and anterior mediastinum using a robotic-assisted thoracoscopic approach in a patient with a prior left thoracotomy and pleurodesis.

针对孤立肺转移灶的转移灶切除术可提高经过严格筛选的患者的无病生存率和总生存率。在可行的情况下,微创楔形切除术是首选方法。然而,同侧胸腔充满敌意会阻碍手术切除。在本报告中,我们描述了使用机器人辅助胸腔镜方法通过右胸和前纵隔切除舌状体孤立转移瘤的情况,该患者之前接受过左胸切开术和胸膜穿刺术。
{"title":"The Scenic Route: Lingular Metastasectomy Through the Right Chest","authors":"","doi":"10.1016/j.atssr.2024.03.010","DOIUrl":"10.1016/j.atssr.2024.03.010","url":null,"abstract":"<div><p>Metastasectomy for isolated pulmonary metastasis can improve disease-free and overall-survival in well-selected patients. When feasible, a minimally invasive wedge resection is the preferred approach. However, a hostile ipsilateral chest can hinder surgical resection. In this report, we describe the resection of an isolated metastasis in the lingula through the right chest and anterior mediastinum using a robotic-assisted thoracoscopic approach in a patient with a prior left thoracotomy and pleurodesis.</p></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772993124001797/pdfft?md5=7f7cdce0ebe98618207694b47535ec4d&pid=1-s2.0-S2772993124001797-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140781975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Variations in Perioperative Thromboprophylaxis Practices: Do the Guidelines Need a Closer Look? 围手术期血栓预防措施的差异:指南是否需要仔细研究?
Pub Date : 2024-09-01 DOI: 10.1016/j.atssr.2024.04.014

Background

In 2022, the American Association for Thoracic Surgery (AATS) and the European Society of Thoracic Surgeons (ESTS) published joint guidelines regarding the timing, duration, and choice of agent for perioperative venous thromboembolism prophylaxis for thoracic cancer patients. Now, 1 year after their release, we looked to assess practices and general adherence to these recommendations.

Methods

We conducted a survey among board-certified/board-eligible thoracic surgeons in the United States, between July and October 2023.

Results

A total of 103 board-certified thoracic surgeons responded to the survey. Over half of the surgeons reported using preoperative chemical thromboprophylaxis routinely for lobectomy/sublobar resections (56.3%), pneumonectomy/extended lung resections (64.1%), and esophagectomy (67%). Over two thirds of thoracic surgeons limited the duration of postoperative chemical thromboprophylaxis to the patient’s length of hospital stay and never administered chemoprophylaxis post-discharge. Among surgeons who always continued chemical thromboprophylaxis post-discharge, low-molecular-weight heparin (LMWH) was the most commonly used agent (>70%), followed by direct oral anticoagulants (13.8%-16.7%). Only 33.3% of surgeons prescribing post-discharge chemical thromboprophylaxis after lobectomy/sublobar resections continued prophylaxis up to 4 weeks postoperatively.

Conclusions

Contrary to the 2022 joint AATS/ESTS guidelines, the majority of surveyed thoracic surgeons in the United States do not routinely prescribe postoperative thromboprophylaxis after lung and esophageal cancer resections. The dogma of routine extended thromboprophylaxis must be reevaluated as modern minimally invasive thoracic surgery allows for very earlier ambulation and enhanced recovery. There is a need for randomized controlled trials exploring the utility of extended thromboprophylaxis and newer agents such as direct oral anticoagulants.

背景2022年,美国胸外科协会(AATS)和欧洲胸外科医师协会(ESTS)发布了关于胸外科癌症患者围手术期静脉血栓栓塞预防的时间、持续时间和药物选择的联合指南。现在,在指南发布 1 年后,我们希望对这些建议的实践和总体遵守情况进行评估。方法我们在 2023 年 7 月至 10 月期间对美国获得医学会认证/有资格获得医学会认证的胸外科医生进行了一项调查。超过半数的外科医生表示,在肺叶切除术/肺下叶切除术(56.3%)、肺切除术/肺扩大切除术(64.1%)和食管切除术(67%)中常规使用术前化学血栓预防措施。超过三分之二的胸外科医生将术后化学血栓预防措施的持续时间限制在患者的住院时间内,并且从未在患者出院后实施化学预防措施。在出院后始终坚持化学血栓预防的外科医生中,低分子量肝素(LMWH)是最常用的药物(70%),其次是直接口服抗凝剂(13.8%-16.7%)。结论与 2022 年 AATS/ESTS 联合指南相反,在美国接受调查的胸外科医生中,大多数人在肺癌和食管癌切除术后不按常规处方进行术后血栓预防。由于现代胸腔镜微创手术可以更早下床活动并促进恢复,因此必须重新评估常规延长血栓预防的教条。有必要进行随机对照试验,探索延长血栓预防措施和更新药物(如直接口服抗凝剂)的效用。
{"title":"Variations in Perioperative Thromboprophylaxis Practices: Do the Guidelines Need a Closer Look?","authors":"","doi":"10.1016/j.atssr.2024.04.014","DOIUrl":"10.1016/j.atssr.2024.04.014","url":null,"abstract":"<div><h3>Background</h3><p>In 2022, the American Association for Thoracic Surgery (AATS) and the European Society of Thoracic Surgeons (ESTS) published joint guidelines regarding the timing, duration, and choice of agent for perioperative venous thromboembolism prophylaxis for thoracic cancer patients. Now, 1 year after their release, we looked to assess practices and general adherence to these recommendations.</p></div><div><h3>Methods</h3><p>We conducted a survey among board-certified/board-eligible thoracic surgeons in the United States, between July and October 2023.</p></div><div><h3>Results</h3><p>A total of 103 board-certified thoracic surgeons responded to the survey. Over half of the surgeons reported using preoperative chemical thromboprophylaxis routinely for lobectomy/sublobar resections (56.3%), pneumonectomy/extended lung resections (64.1%), and esophagectomy (67%). Over two thirds of thoracic surgeons limited the duration of postoperative chemical thromboprophylaxis to the patient’s length of hospital stay and never administered chemoprophylaxis post-discharge. Among surgeons who always continued chemical thromboprophylaxis post-discharge, low-molecular-weight heparin (LMWH) was the most commonly used agent (&gt;70%), followed by direct oral anticoagulants (13.8%-16.7%). Only 33.3% of surgeons prescribing post-discharge chemical thromboprophylaxis after lobectomy/sublobar resections continued prophylaxis up to 4 weeks postoperatively.</p></div><div><h3>Conclusions</h3><p>Contrary to the 2022 joint AATS/ESTS guidelines, the majority of surveyed thoracic surgeons in the United States do not routinely prescribe postoperative thromboprophylaxis after lung and esophageal cancer resections. The dogma of routine extended thromboprophylaxis must be reevaluated as modern minimally invasive thoracic surgery allows for very earlier ambulation and enhanced recovery. There is a need for randomized controlled trials exploring the utility of extended thromboprophylaxis and newer agents such as direct oral anticoagulants.</p></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772993124001955/pdfft?md5=84ea810af1add8e997daf3f11611478c&pid=1-s2.0-S2772993124001955-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141051921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung Transplantation for Familial Diffuse Pulmonary Ossification 肺移植治疗家族性弥漫性肺骨化症
Pub Date : 2024-09-01 DOI: 10.1016/j.atssr.2024.02.015

We report 3 cases of extremely rare familial idiopathic diffuse pulmonary ossification, 2 of 3 received lung transplantation and the other is listed for lung transplantation. The clinical courses of family members varied greatly, and rapid deterioration could occur; therefore, early and close examination is recommended for transplant registration. During transplantation, the lungs appeared and felt exactly like a “pumice stone” and could not collapse, and good visual field was not easily obtained. Both patients had no recurrence of pulmonary ossification for more than 2 years.

我们报告了3例极其罕见的家族性特发性弥漫性肺骨化症,其中2例接受了肺移植手术,另1例已列入肺移植手术名单。家族成员的临床病程差异很大,病情可能迅速恶化,因此建议在登记移植时尽早进行密切检查。移植过程中,肺部外观和感觉完全像 "浮石",无法塌陷,不易获得良好视野。两名患者在两年多的时间里都没有再出现肺骨化。
{"title":"Lung Transplantation for Familial Diffuse Pulmonary Ossification","authors":"","doi":"10.1016/j.atssr.2024.02.015","DOIUrl":"10.1016/j.atssr.2024.02.015","url":null,"abstract":"<div><p>We report 3 cases of extremely rare familial idiopathic diffuse pulmonary ossification, 2 of 3 received lung transplantation and the other is listed for lung transplantation. The clinical courses of family members varied greatly, and rapid deterioration could occur; therefore, early and close examination is recommended for transplant registration. During transplantation, the lungs appeared and felt exactly like a “pumice stone” and could not collapse, and good visual field was not easily obtained. Both patients had no recurrence of pulmonary ossification for more than 2 years.</p></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772993124001189/pdfft?md5=a169b8068ff83cce2ceb4013b55aa80c&pid=1-s2.0-S2772993124001189-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140408099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geographic Variation in the Utilization of Services Surrounding Lung Cancer Resection 肺癌切除术周围服务利用的地域差异
Pub Date : 2024-09-01 DOI: 10.1016/j.atssr.2024.02.007

Background

As value-based care models continue to gain emphasis, along with the need for improved profiling across the continuum of lung cancer care, a better understanding of geographic variation in utilization of services surrounding episodes of care is needed.

Methods

In this retrospective cohort study of patients undergoing lung cancer resection from 2017 to 2019, we examined geographic variation in utilization of services surrounding episodes of lung cancer resection. We utilized hierarchical logistic regression models to determine risk-adjusted utilization of services. This study utilized inpatient and ambulatory databases across 4 states: New Jersey, Pennsylvania, Florida, and Maryland. All patients undergoing lung cancer resection were included. The primary outcome was risk-adjusted utilization of services.

Results

Mean risk-adjusted utilization of ambulatory procedures across all hospital referral regions (HRRs) was 34.1% (95% CI 30.7%-37.6%), while the individual HRR utilization varied from 10.9% to 54.9% (P < .01). Mean risk-adjusted utilization of inpatient admissions in the 6 months prior to surgery was 15.3% (95% CI 13.9%-16.7%), ranging from 7.4% to 24.7% (P = .07) across HRRs. Finally, mean risk-adjusted utilization of inpatient hospitalizations in the 6 months following surgery was 19.4% (95% CI 17.7-21.0%), ranging from 10.0% to 33.6% (P = .19) across HRRs.

Conclusions

Overall, we observed that utilization of ambulatory services varied significantly across HRRs, while inpatient utilization did not demonstrate significant variation. Given these findings, there may be geographic drivers of variation in the utilization of services surrounding lung cancer resection.

背景随着以价值为基础的护理模式不断受到重视,以及需要改善肺癌护理整个过程的概况,我们需要更好地了解围绕护理事件的服务利用率的地域差异。方法在这项对 2017 年至 2019 年接受肺癌切除术的患者进行的回顾性队列研究中,我们考察了围绕肺癌切除术事件的服务利用率的地域差异。我们利用分层逻辑回归模型来确定风险调整后的服务利用率。本研究使用了 4 个州的住院和门诊数据库:新泽西州、宾夕法尼亚州、佛罗里达州和马里兰州。所有接受肺癌切除术的患者均被纳入研究范围。结果 所有医院转诊地区(HRRs)门诊手术的平均风险调整利用率为 34.1%(95% CI 30.7%-37.6%),而单个 HRR 利用率从 10.9% 到 54.9% 不等(P <.01)。手术前 6 个月住院病人的平均风险调整使用率为 15.3% (95% CI 13.9%-16.7%) ,各 HRR 的使用率从 7.4% 到 24.7% 不等(P = .07)。最后,经风险调整后,手术后 6 个月内住院病人的平均使用率为 19.4% (95% CI 17.7-21.0%),各 HRRs 的使用率从 10.0% 到 33.6% 不等(P = .19)。鉴于这些发现,肺癌切除术相关服务的利用率可能存在地域差异。
{"title":"Geographic Variation in the Utilization of Services Surrounding Lung Cancer Resection","authors":"","doi":"10.1016/j.atssr.2024.02.007","DOIUrl":"10.1016/j.atssr.2024.02.007","url":null,"abstract":"<div><h3>Background</h3><p>As value-based care models continue to gain emphasis, along with the need for improved profiling across the continuum of lung cancer care, a better understanding of geographic variation in utilization of services surrounding episodes of care is needed.</p></div><div><h3>Methods</h3><p>In this retrospective cohort study of patients undergoing lung cancer resection from 2017 to 2019, we examined geographic variation in utilization of services surrounding episodes of lung cancer resection. We utilized hierarchical logistic regression models to determine risk-adjusted utilization of services. This study utilized inpatient and ambulatory databases across 4 states: New Jersey, Pennsylvania, Florida, and Maryland. All patients undergoing lung cancer resection were included. The primary outcome was risk-adjusted utilization of services.</p></div><div><h3>Results</h3><p>Mean risk-adjusted utilization of ambulatory procedures across all hospital referral regions (HRRs) was 34.1% (95% CI 30.7%-37.6%), while the individual HRR utilization varied from 10.9% to 54.9% (<em>P</em> &lt; .01). Mean risk-adjusted utilization of inpatient admissions in the 6 months prior to surgery was 15.3% (95% CI 13.9%-16.7%), ranging from 7.4% to 24.7% (<em>P</em> = .07) across HRRs. Finally, mean risk-adjusted utilization of inpatient hospitalizations in the 6 months following surgery was 19.4% (95% CI 17.7-21.0%), ranging from 10.0% to 33.6% (<em>P</em> = .19) across HRRs.</p></div><div><h3>Conclusions</h3><p>Overall, we observed that utilization of ambulatory services varied significantly across HRRs, while inpatient utilization did not demonstrate significant variation. Given these findings, there may be geographic drivers of variation in the utilization of services surrounding lung cancer resection.</p></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772993124001104/pdfft?md5=1591b6643128a670ccf177b50929efcd&pid=1-s2.0-S2772993124001104-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140269358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of thoracic surgery short reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1